Literature DB >> 15770483

Soluble CD21 in sera and synovial fluid of arthritic patients.

Thomas Grottenthaler1, Johannes von Kempis, Sigune Goldacker, Harald Illges.   

Abstract

Soluble CD21 (sCD21) is the ectodomain of the CD21 glycoprotein released by shedding from the cellular membrane. The ectodomain of CD21 is capable of binding complement fragments, Epstein-Barr virus (EBV) and CD23. Functionally sCD21 can activate monocytes and abrogate B-cell/follicular dendritic cell interaction, thereby inhibiting antibody production by antigen primed B cells. Levels of sCD21 vary in several clinical conditions. Here we analyzed sCD21 in synovial fluids and sera in arthritic patients. sCD21 concentrations were consistently lower in synovial fluids compared to paired sera samples from the same patients. In contrast to healthy donors, sCD21 levels are significantly reduced in rheumatoid arthritis patient's sera. Potential causes and consequences of the data are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15770483     DOI: 10.1007/s00296-004-0541-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  21 in total

Review 1.  Functional properties of soluble CD21.

Authors:  V Frémeaux-Bacchi; J P Kolb; S Rakotobé; M D Kazatchkine; E M Fischer
Journal:  Immunopharmacology       Date:  1999-05

2.  Reduced expression of the complement receptor type 2 (CR2, CD21) by synovial fluid B and T lymphocytes.

Authors:  H Illges; M Braun; H H Peter; I Melchers
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

3.  Properties of soluble CR2 in human serum.

Authors:  N R Ling; B Brown
Journal:  Immunobiology       Date:  1992-08       Impact factor: 3.144

4.  Soluble CD21 induces activation and differentiation of human monocytes through binding to membrane CD23.

Authors:  V Frémeaux-Bacchi; J P Aubry; J Y Bonnefoy; M D Kazatchkine; J P Kolb; E M Fischer
Journal:  Eur J Immunol       Date:  1998-12       Impact factor: 5.532

5.  Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses.

Authors:  D Qin; J Wu; M C Carroll; G F Burton; A K Szakal; J G Tew
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

6.  Alpha 1 antitrypsin (PI) phenotypes in two rheumatic diseases: a reappraisal of the association of PI subtypes in rheumatoid arthritis.

Authors:  S S Papiha; B Pal; D Walker; P Mangion; M A Hossain
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

7.  Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis.

Authors:  M Masilamani; J von Kempis; H Illges
Journal:  Rheumatology (Oxford)       Date:  2003-07-16       Impact factor: 7.580

8.  B cell activation leads to shedding of complement receptor type II (CR2/CD21).

Authors:  Madhan Masilamani; Daniela Kassahn; Stefan Mikkat; Michael O Glocker; Harald Illges
Journal:  Eur J Immunol       Date:  2003-09       Impact factor: 5.532

9.  Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases.

Authors:  B Gu; L J Bendall; J S Wiley
Journal:  Blood       Date:  1998-08-01       Impact factor: 22.113

10.  Innate immunity as a hired gun: but is it rheumatoid arthritis?

Authors:  Maripat Corr; Gary S Firestein
Journal:  J Exp Med       Date:  2002-04-15       Impact factor: 14.307

View more
  2 in total

1.  Enhanced CD21 expression and shedding in chronic lymphatic leukemia: a possible pathomechanism in disease progression.

Authors:  Hui Zhi Low; Dorothee Hilbrans; Ingo G H Schmidt-Wolf; Harald Illges
Journal:  Int J Hematol       Date:  2012-08-17       Impact factor: 2.490

2.  Systemic reduction of soluble complement receptor II/CD21 during pregnancy to levels reminiscent of autoimmune disease.

Authors:  Madhan Masilamani; Narendiran Rajasekaran; Anjana Singh; Hui-Zhi Low; Kerstin Albus; Swantje Anders; Frank Behne; Peter Eiermann; Katharina König; Clarissa Mindnich; Teodora Ribarska; Harald Illges
Journal:  Rheumatol Int       Date:  2008-05-24       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.